Free shipping on all orders over $ 500

TD-4208

Cat. No. M6127

All AbMole products are for research use only, cannot be used for human consumption.

TD-4208 Structure
Synonym:

Revefenacin; GSK1160724

Size Price Availability Quantity
10mM*1mL in DMSO USD 108 In stock
1mg USD 34 In stock
2mg USD 48 In stock
5mg USD 84 In stock
10mg USD 148 In stock
50mg USD 398 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Revefenacin (TD-4208; GSK1160724) is a novel long-acting muscarinic antagonist currently in clinical development for the treatment of respiratory diseases, including bronchospasm due to COPD. The purpose of our studies was to characterize the in vivo bronchoprotective and antisialagogue effect of this new agent. In two preclinical species, we showed that inhaled TD-4208 produces sustained bronchoprotective activity up to 24 hours after dosing. Moreover, after 7-day repeat dosing in rats, equieffective bronchoprotective doses of TD-4208 inhibited salivation to a much lesser extent than the other two muscarinic antagonists. Thus, TD-4208 exhibits greater lung selectivity than either tiotropium or glycopyrronium.

Protocol (for reference only)
Cell Experiment
Cell lines CHO-K1 (Chinese hamster ovary-K1) cell lines
Preparation method CHO-K1 (Chinese hamster ovary-K1) cell lines stably expressing hM1, hM3, M4-G16α and cM5 mAChR subtypes, respectively, were grown to near confluency in medium consisting of HAM's F-12 supplemented with 10% FBS and 250 μg mL-1 Geneticin. The chimpanzee M5 receptor was utilized as a surrogate of the human M5 due to intellectual property restrictions surrounding use of the latter in cell-based studies. Cells were gently washed and treated for 40 minutes at 37°C with the membrane permeable, calcium sensitive dye, FLUO-4AM and, following a wash, were then incubated with increasing concentrations of revefenacin for 20 minutes at 37°C. The cells were stimulated with oxotremorine at a concentration required to elicit 90% of the maximal response (EC90). The change in fluorescence was measured using a FLIPR®-Tetra.
Concentrations
Incubation time 20 minutes
Animal Experiment
Animal models Dogs
Formulation
Dosages 3, 10, and 30 µg/kg
Administration i.v.
Chemical Information
Molecular Weight 597.75
Formula C35H43N5O4
CAS Number 864750-70-9
Form Solid
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Mastrodicasa MA, et al. Expert Opin Investig Drugs. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.

[2] Pulido-Rios MT, et al. J Pharmacol Exp Ther. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.

Related AChR/AChE Products
VU 0255035

VU 0255035 is a highly selective M1 muscarinic acetylcholine receptor (mAChR) antagonist (Ki = 14.87 nM).

Fesoterodine fumarate

Fesoterodine fumarate (Toviaz) is a novel muscarinic receptor antagonist.

SVT-40776

SVT-40776 is a novel M3 muscarinic receptor antagonist.

Aniracetam

Aniracetam is a compound that promotes intellectual development and neuroprotection.

Biperiden hydrochloride

Biperiden (KL 373) hydrochloride is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system.

  Catalog
Abmole Inhibitor Catalog




Keywords: TD-4208, Revefenacin; GSK1160724 supplier, AChR/AChE, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.